Takayasu Arteritis
Takayasu arteritis is an uncommon large vessel vasculitis that involves the aorta and its major branches, in addition to the pulmonary and coronary arteries. Leading the way in rare cardiovascular disease research, Protheragen is a one-stop service provider for drug discovery and development services for these types of conditions such as Takayasu arteritis. With the latest technology and know-how, we save you time and effort on your drug development.
Introduction to Takayasu Arteritis
Takayasu arteritis is a rare type of chronic non-specific vasculitis of unknown origin that affects the aorta and its main branches, and the coronary and pulmonary vessels. There are few such diseases with a high incidence of heart involvement as Takayasu arteritis among all types of vasculitis. It predominantly occurs in young women and the initial symptoms are atypical in the second and third decades of life. It is also often defined as a rare disease, with an occurrence rate of 1 to 3 per million individuals in the USA and Europe.
Fig.1 Biomarkers assessing disease activity and damage in Takayasu arteritis. (Misra, D. P., et al., 2023)Pathogenesis of Takayasu Arteritis
Immunity inflammation and genetic components are regarded as the three main actors involved in the pathogenesis of Takayasu arteritis. At present, T-cell-mediated cellular immunity, B-cell-mediated humoral immunity, and innate and adaptative immunity have been recognized to be involved in the etiology of this disease.
The primary histopathology changes may be as follows: it seems that cellular infiltrate, including CD4 T cells, CD8 T cells, NK cells, γδ T lymphocytes, macrophages can be found in early vascular lesion; Then granulocytes, giant cells, and granuloma formation can be observed in the media of involved arteries, especially; Finally, extensive fibrosis and intimal hyperplasia develop and may cause aortic thickening (or stenosis, occlusion), occasionally aortic dissection/aneurysm formation occurred.
Fig.2 Angiographic methods in Takayasu arteritis. (Misra, D. P., et al., 2023)Therapeutics Development for Takayasu Arteritis
| Drug Name | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Bosentan | Endothelin receptor blockade to prevent the vasoconstrictor and inflammatory effects of endothelin-1 in large arteries. | Endothelin-1 | NCT06887062 | Phase II |
| Vunakizumab | Modulating selects immune responses to suppress vascular inflammation and ameliorate arterial damage. | IL-17A | NCT06766552 | N/A |
| Baricitinib | Inhibition of Janus kinase 1 and 2 (JAK1 and JAK2) which may diminish pro-inflammatory cytokine signaling and vascular inflammation. | JAK1, JAK2 | NCT06662721 | Phase II |
| Upadacitinib | Preferential inhibition of JAK1 decreases pro-inflammatory cytokine signals and restricts immune-mediated vascular inflammation. | JAK1 | NCT04161898 | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
With a full range of services across diagnostics, therapeutic validation, and disease model development, we are well-placed to help meet your research and development goals. We've combined years of experience in pharmacokinetic studies and toxicology testing to offer you a complete gamut of preclinical services. Our state-of-the-art facilities, coupled with our experienced scientific team take care of every step in the process of your drug development with accuracy and speed.
Therapeutic Development Services
Animal Model Development for Takayasu Arteritis
Developing animal models for Takayasu Arteritis is crucial in advancing drug discovery and development for this rare cardiovascular disease. These models provide invaluable insights into the disease's pathophysiology, allowing researchers to explore new therapeutic targets and assess the efficacy and safety of potential therapeutics. Leveraging our extensive expertise in cardiovascular disease modeling, our company offers customized animal model development services specifically tailored to Takayasu arteritis research.
- IL-1Ra Deficient Model
This model involves mice genetically engineered to lack the interleukin-1 receptor antagonist (IL-1Ra).
- IFNgammaR-/- Model with HV68 Infection
These IFNgammaR-/- models are infected with herpes virus 68 (HV68) and develop severe large-vessel panarteritis that is quite similar to the vascular inflammation profile observed in Takayasu arteritis individuals.
Dedicated to the pursuit of excellence and innovation, Protheragen become a trusted ally in the battle against rare cardiovascular disease. We fast-track the path to effective therapeutics: from the initial idea to the preclinical potential. Contact us today to learn more about how our tailored service can match your specific requirements and help drive your projects forward.
Reference
- Misra, Durga Prasanna et al. "Management of Takayasu arteritis." Best practice & research. Clinical rheumatology 37.1 (2023): 101826.
For research use only, not for clinical use.